Dr Anthony Matthew Bielawski, MD | |
200 W Arbor Dr, San Diego, CA 92103-9000 | |
(800) 926-8273 | |
Not Available |
Full Name | Dr Anthony Matthew Bielawski |
---|---|
Gender | Male |
Speciality | Emergency Medicine |
Location | 200 W Arbor Dr, San Diego, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528038346 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | A119182 (California) | Primary |
Entity Name | Regents Of The University Of California |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780870899 PECOS PAC ID: 6406760131 Enrollment ID: O20031117000940 |
News Archive
Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Researchers say that the results are so compelling that cancer funding agencies should be eager to support clinical trials to evaluate its therapeutic role in a variety of cancers.
AGA Medical Holdings, Inc. today announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient.
› Verified 6 days ago
Entity Name | Regents Of The University Of California |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1578672184 PECOS PAC ID: 3577476761 Enrollment ID: O20031211000464 |
News Archive
Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Researchers say that the results are so compelling that cancer funding agencies should be eager to support clinical trials to evaluate its therapeutic role in a variety of cancers.
AGA Medical Holdings, Inc. today announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient.
› Verified 6 days ago
Entity Name | Inpatient Services Of California A Medical Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1609019215 PECOS PAC ID: 3274421532 Enrollment ID: O20040413000789 |
News Archive
Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Researchers say that the results are so compelling that cancer funding agencies should be eager to support clinical trials to evaluate its therapeutic role in a variety of cancers.
AGA Medical Holdings, Inc. today announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient.
› Verified 6 days ago
Entity Name | Chase Dennis Emergency Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1033152350 PECOS PAC ID: 2264345172 Enrollment ID: O20040729000498 |
News Archive
Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Researchers say that the results are so compelling that cancer funding agencies should be eager to support clinical trials to evaluate its therapeutic role in a variety of cancers.
AGA Medical Holdings, Inc. today announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient.
› Verified 6 days ago
Entity Name | Uc San Diego Health Community Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1659864247 PECOS PAC ID: 3971849175 Enrollment ID: O20190109000943 |
News Archive
Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Researchers say that the results are so compelling that cancer funding agencies should be eager to support clinical trials to evaluate its therapeutic role in a variety of cancers.
AGA Medical Holdings, Inc. today announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Anthony Matthew Bielawski, MD Po Box 232410, San Diego, CA 92193-2410 Ph: () - | Dr Anthony Matthew Bielawski, MD 200 W Arbor Dr, San Diego, CA 92103-9000 Ph: (800) 926-8273 |
News Archive
Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.
Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.
Researchers say that the results are so compelling that cancer funding agencies should be eager to support clinical trials to evaluate its therapeutic role in a variety of cancers.
AGA Medical Holdings, Inc. today announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient.
› Verified 6 days ago
Sarah Wilkinson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr # 8819, San Diego, CA 92103 Phone: 956-458-9885 | |
Dr. Ramandeep Singh Dhillon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5454 El Cajon Blvd, San Diego, CA 92115 Phone: 619-515-2400 | |
Mina Kyrollus Ghobrial, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 800-926-8273 Fax: 888-539-8781 | |
Dr. Timothy Stuart Hinman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 4th Ave, San Diego, CA 92101 Phone: 858-499-2600 | |
Dr. Peter D. Aldrich, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 15025 Innovation Dr, San Diego, CA 92128 Phone: 858-554-8638 | |
Dr. Matthew J. Perl, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 15004 Innovation Dr, San Diego, CA 92128 Phone: 858-605-7171 | |
Jeffrey Adam Bush, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 4647 Zion Ave, San Diego, CA 92120 Phone: 619-528-5000 |